Clinical trial NCT03182582: Efficacy of Laser Debridement on Pain and Bacterial Load in Chronic Wounds
Official title: Efficacy of the Er:YAG Laser Debridement on Patient-Reported Pain and Bacterial Load in Chronic Wounds
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wound Open
Chronic Venous Hypertension (Idiopathic) With Ulcer
Diabetic Foot Ulcer
Keywords: Laser Debridement
Debridement
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2017-06-09
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: A portion of the patients will be randomized to sharp debridement first, then laser for the second debridement. The other portion will undergo this in the opposite order.
Primary purpose: TREATMENT

Brief summary: Bacterial load is frequently associated with impaired healing of chronic wounds. As well, sharp debridement is often associated with pain, causing patient distress, and thereby occasionally contributing to inadequacy of debridement, leading to a delay in wound healing. The purpose of this study is to assess the efficacy of the Sciton Laser in reducing bacterial load and patient distress in patients with chronic wounds, in efforts to expedite the wound healing process.

Detailed description: Chronic wounds are a debilitating affliction, affecting a substantial portion of the population worldwide and incurring staggering healthcare economic costs (1,2). Included among chronic wounds are venous leg ulcers, which are known to cause considerable pain, and can impact patient quality of life, thereby complicating wound care (3). The exact pathophysiology and etiology of the prolonged course of chronic wounds are poorly understood, but are thought to be multi-factorial in nature. Given the exposure of chronic wounds to the environment, they harbor a diverse microbial flora. Specifically, there is evidence that biofilm produced by these microbes are a large contributor to their non-healing nature (4). Debridement is considered an integral part of wound management with its ability to remove necrotic tissue and bacterial biofilm, in addition to stimulating release of cytokines and growth factors that promote wound healing (5). However, sharp debridement, the gold standard in wound care, is often ineffective for painful wounds.

The effect of lasers on wound healing have been well-studied both in in vitro and in vivo models. Beneficial effects of low-level laser therapy in wound healing in animal and human studies has been established. However, extrapolation of this data is limited by study design and light dosimetry (6). Laser energy used for surgical excision is a lesser-known debridement technique that has been largely limited to burn scar treatment (7,8,9,10). Lasers are electro-optical devices that emit a focused beam of intense monochromatic light in the visible and infrared radiation spectrums. Since their start in the 1960s, lasers have been successfully utilized in many fields of medicine. Lasers for wound debridement began in the 1970s, with the successful report of a continuous-beam carbon dioxide (CO2) laser used for skin graft preparation of infected decubitus ulcers (11). Laser debridement is based on the controlled vaporization of the superficial layers of the wound bed. This results in the removal of the tissue containing unwanted microbial and necrotic particles. The laser type and the number of passes performed determine the depth of tissue ablation (12). Unlike other methods dependent on the clinician's manual control, laser debridement is electronically controlled, improving precision and reducing the risk of healthy tissue damage. Advantages of laser debridement include precision and uniformity of tissue ablation, which reduces trauma to the wound bed, improving patient comfort. To reduce thermal damage to healthy tissue, several improvements in laser technology have been made over the years. By utilizing a pulsed-beam system, laser energy is delivered in high-power, rapid succession pulses, resulting in short duration and high temperature exposure of target tissue, thereby minimizing thermal injury.

Erbium:YAG (Er:YAG) lasers, with a wavelength of 2940-nm are widely used in the dermatologic community for skin resurfacing, for anti-aging and acne-related purposes (13). Skin ablation with the erbium laser is very precise, and allows for accurate assessment of the resurfacing depth (12,14,15). Since Er:YAG laser energy has greater than twelve times more water absorption efficiency than CO2 lasers, water in the tissue is rapidly expanded to eject the charred debris from the wound surface without leaving behind a necrotic eschar (12,16,17). The Er:YAG laser provides distinct advantages in precise ablation control and the reduction of residual necrotic tissue burden with minimal procedural discomfort, making the Er:YAG laser the most suitable device for laser wound debridement. Preliminary studies demonstrate remarkable patient pain reduction after laser debridement, resulting in more thorough removal of necrotic tissue and biofilm/bacterial load. Additionally, the extent of laser debridement is determined by the laser settings, as opposed to the individual operator's dexterity and skill, thereby providing better control over the wound bed preparation, producing more predictable and reproducible outcomes.

Eligibility criteria: Inclusion Criteria:

* Aged eighteen years or older
* Having a chronic wound (as defined by lack of at least 50% reduction in wound surface area over a period of four weeks)
* No clinical evidence of active wound bed infection
* No exposure of any vital structure (i.e., tendon, bone, vessel)
* Has signed the informed consent form prior to any study protocol related procedure
* Willing and able to adhere to protocol requirements

Exclusion Criteria:

* Any unstable medical condition that would cause the study treatment to be detrimental to the subject, as judged by the Principle Investigator
* Documented medical history of significant cardiac, pulmonary, gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), metabolic, neurological, hepatic or nephrologic disease would impede the subject's participation, as judged by the Principle Investigator
* Documented medical history of immunosuppression, immune deficiency disorder, or currently using immunosuppressive medications
* Having clinical presentation of active osteomyelitis
* Pregnancy or lactation
* Participation in another clinical study involving ulcers within thirty days prior to enrollment

Primary outcomes:
measure: Pain With Debridement
timeFrame: Day 1 of the respective procedure (immediately following)
measure: Bacterial Load Pre- and Post-Laser Debridement
timeFrame: Day 1 of the laser procedure (immediately before and after)
measure: Bacterial Load Pre- and Post-Sharp Debridement
timeFrame: Day 1 of the sharp procedure (immediately before and after)
Secondary outcomes:
measure: Patient Preference
timeFrame: 2 weeks
measure: Percent Change in Wound Size- Immediately Post-debridement
timeFrame: Day 1 of the respective procedure (immediately after)
measure: Percent Change in Wound Size - 1 Week Post-debridement
timeFrame: 1 week following respective procedure
Other outcomes:
Locations:
Study officials:
affiliation: Clinical Trial Coordinator
name: Shannon Meyer, CCRC
role: STUDY_DIRECTOR
References:
citation: Hill KE, Davies CE, Wilson MJ, Stephens P, Harding KG, Thomas DW. Molecular analysis of the microflora in chronic venous leg ulceration. J Med Microbiol. 2003 Apr;52(Pt 4):365-369. doi: 10.1099/jmm.0.05030-0.
citation: Collins L, Seraj S. Diagnosis and treatment of venous ulcers. Am Fam Physician. 2010 Apr 15;81(8):989-96.
citation: Palfreyman S. Assessing the impact of venous ulceration on quality of life. Nurs Times. 2008 Oct 14-20;104(41):34-7.
citation: Falanga V. Chronic wounds: pathophysiologic and experimental considerations. J Invest Dermatol. 1993 May;100(5):721-5. doi: 10.1111/1523-1747.ep12472373. No abstract available.
citation: Brem H, Stojadinovic O, Diegelmann RF, Entero H, Lee B, Pastar I, Golinko M, Rosenberg H, Tomic-Canic M. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med. 2007 Jan-Feb;13(1-2):30-9. doi: 10.2119/2006-00054.Brem.
citation: Percival SL, Francolini I, Donelli G. Low-level laser therapy as an antimicrobial and antibiofilm technology and its relevance to wound healing. Future Microbiol. 2015;10(2):255-72. doi: 10.2217/fmb.14.109.
citation: Evison D, Brown RF, Rice P. The treatment of sulphur mustard burns with laser debridement. J Plast Reconstr Aesthet Surg. 2006;59(10):1087-93. doi: 10.1016/j.bjps.2006.02.010. Epub 2006 Jul 7.
citation: Graham JS, Schomacker KT, Glatter RD, Briscoe CM, Braue EH Jr, Squibb KS. Efficacy of laser debridement with autologous split-thickness skin grafting in promoting improved healing of deep cutaneous sulfur mustard burns. Burns. 2002 Dec;28(8):719-30. doi: 10.1016/s0305-4179(02)00198-5.
citation: Lam DG, Rice P, Brown RF. The treatment of Lewisite burns with laser debridement---'lasablation'. Burns. 2002 Feb;28(1):19-25. doi: 10.1016/s0305-4179(01)00078-x.
citation: Reynolds N, Cawrse N, Burge T, Kenealy J. Debridement of a mixed partial and full thickness burn with an erbium:YAG laser. Burns. 2003 Mar;29(2):183-8. doi: 10.1016/s0305-4179(02)00247-4. No abstract available.
citation: Stellar S, Meijer R, Walia S, Mamoun S. Carbon dioxide laser debridement of decubitus ulcers: followed by immediate rotation flap or skin graft closure. Ann Surg. 1974 Feb;179(2):230-7. doi: 10.1097/00000658-197402000-00022. No abstract available.
citation: Alster TS, Lupton JR. Erbium:YAG cutaneous laser resurfacing. Dermatol Clin. 2001 Jul;19(3):453-66. doi: 10.1016/s0733-8635(05)70286-2.
citation: Pozner JN, Goldberg DJ. Superficial erbium:YAG laser resurfacing of photodamaged skin. J Cosmet Laser Ther. 2006 Jun;8(2):89-91. doi: 10.1080/14764170600717852.
citation: Bass LS. Erbium:YAG laser skin resurfacing: preliminary clinical evaluation. Ann Plast Surg. 1998 Apr;40(4):328-34. doi: 10.1097/00000637-199804000-00002.
citation: Weinstein C. Computerized scanning erbium:YAG laser for skin resurfacing. Dermatol Surg. 1998 Jan;24(1):83-9. doi: 10.1111/j.1524-4725.1998.tb04058.x.
citation: Weinstein C, Pozner J, Scheflan M, Achauer BM. Combined Erbium:YAG Laser Resurfacing and Face Lifting. Plast Reconstr Surg. 2001 Feb;107(2):593-594. doi: 10.1097/00006534-200102000-00046. No abstract available.
citation: Roberts TL 3rd, Pozner JN. Lasers, facelifting, and the future. Clin Plast Surg. 2000 Apr;27(2):293-9. No abstract available.